Evidence map›Paper›PMID 27032639›Full record

Trial reportJournal of nephrology2016

Montelukast as an add-on treatment in steroid dependant nephrotic syndrome, randomised-controlled trial.

Magdy Mohamed Zedan, Ahmed El-Refaey, Hosam Zaghloul, Mohamed E A Abdelrahim, Amal Osman, Mohamed M Zedan, Nashwa Eltantawy

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. The renoprotective potential of montelukast: a scoping review.Annals of medicine and surgery (2012) · 2024
    Article
  6. Article
  7. Arachidonic Acid Metabolism and Kidney Inflammation.International journal of molecular sciences · 2019
    Review
  8. Leukotrienes and kidney diseases.Current opinion in nephrology and hypertension · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Magdy Mohamed ZedanFaculty of Medicine, Allergy, Respiratory and Clinical Immunology Unit, Pediatric Department, Mansoura University, Mansoura, Egypt. magdyzedan@yahoo.com.
Ahmed El-RefaeyFaculty of Medicine, Nephrology Unit, Pediatric Department, Mansoura University, Mansoura, Egypt.
Hosam ZaghloulFaculty of Medicine, Clinical Pathology Department, Mansoura University, Mansoura, Egypt.
Mohamed E A AbdelrahimFaculty of Pharmacy, Clinical Pharmacy Department, BeniSuef University, Benisuef, Egypt.
Amal OsmanFaculty of Medicine, Allergy, Respiratory and Clinical Immunology Unit, Pediatric Department, Mansoura University, Mansoura, Egypt.
Mohamed M ZedanFaculty of Medicine, Nephrology Unit, Pediatric Department, Mansoura University, Mansoura, Egypt.
Nashwa EltantawyFaculty of Pharmacy, Clinical Pharmacy Department, BeniSuef University, Benisuef, Egypt.
Mansoura University · EGBeni-Suef University · EGNahda University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe underlying mechanisms of nephrotic syndrome (NS) are still under debate and the need for more effective and less toxic treatment is challenging. We aimed to evaluate the efficacy of montelukast, a leukotriene receptor antagonist as an add-on therapy, and to explore the leukotriene (LT) biology in steroid-dependent nephrotic syndrome (SDNS).

methodsA randomized controlled trial was conducted including 32 patients with SDNS who were randomly assigned to receive standard steroid treatment only [low-dose steroid (LDS) group] or standard steroid therapy plus montelukast (Montelukast group). Urine protein/creatinine ratio, serum albumin, creatinine, cholesterol, and plasma LTs (LTB4/C4/D4/E4) were evaluated in all patients before and after treatment.

resultsAfter treatment, both groups showed a significant decrease of LTB4 and LTC4/D4/E4. Further, the Montelukast group showed a significant decrease in serum creatinine and a significant increase in diastolic blood pressure and protein/creatinine ratio. It also showed a marked decrease in plasma LTC4/D4/E4 compared to the LDS group, although not statistically significant.

conclusionsOur findings highlight the effect of montelukast on renal function, but suggest that the clinical and laboratory efficacy of the addition of montelukast to steroids in maintenance treatment of SDNS is debatable.

Indexed as

AcetatesAdolescentChildCyclopropanesDrug Therapy, CombinationFemaleFollow-Up StudiesGlucocorticoidsHumansKidney Function TestsLeukotriene AntagonistsMaleNephrotic SyndromeQuinolinesSulfidesTreatment OutcomeAcetatesCyclopropanesGlucocorticoidsLeukotriene AntagonistsmontelukastQuinolinesSulfidesLeukotrienesMontelukastSteroid-dependent nephrotic syndrome

Identifiers

PMID27032639
OpenAlexW2332179792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.